# A Study Using Recombinant Human Luteinizing Hormone (r-hLH, Luveris®) in the Treatment of Chinese Women With Hypogonadotropic Hypogonadism

> **NCT01084265** · PHASE3 · COMPLETED · sponsor: **Merck KGaA, Darmstadt, Germany** · enrollment: 31 (actual)

## Conditions studied

- Hypogonadism

## Interventions

- **DRUG:** Recombinant human luteinizing hormone (r-hLH)
- **DRUG:** Recombinant human follicle-stimulating hormone (r-hFSH)
- **DRUG:** Human chorionic gonadotropin (hCG)

## Key facts

- **NCT ID:** NCT01084265
- **Lead sponsor:** Merck KGaA, Darmstadt, Germany
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-02
- **Primary completion:** 2005-12
- **Final completion:** 2005-12
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2013-12-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01084265

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01084265, "A Study Using Recombinant Human Luteinizing Hormone (r-hLH, Luveris®) in the Treatment of Chinese Women With Hypogonadotropic Hypogonadism". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01084265. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*